Portal de Periódicos da CAPES

Tumor Therapy by Immune Recruitment with Bispecific Antibodies

1995; Wiley; Volume: 145; Issue: 1 Linguagem: Inglês

10.1111/j.1600-065x.1995.tb00082.x

1600-065X

Christoph Renner, Michael Pfreundschuh,

CAR-T cell therapy research

Immunological ReviewsVolume 145, Issue 1 p. 179-209 Tumor Therapy by Immune Recruitment with Bispecific Antibodies Christoph Renner, Christoph Renner Med. Klinik I. University of the Saarland. 66421 Homburg/Sar, Germany.Search for more papers by this authorMichael Pfreundschuh, Corresponding Author Michael Pfreundschuh Med. Klinik I. University of the Saarland. 66421 Homburg/Sar, Germany.Michael Pfreundschuh. MD, Med, Klinik I. Universitat des Saarlandes; Oscar-Orth-Str., 66421 Homburg/Saar. Germany. Tel.: 0049-6841-163002. Fax: 0049-6841-163101.Search for more papers by this author Christoph Renner, Christoph Renner Med. Klinik I. University of the Saarland. 66421 Homburg/Sar, Germany.Search for more papers by this authorMichael Pfreundschuh, Corresponding Author Michael Pfreundschuh Med. Klinik I. University of the Saarland. 66421 Homburg/Sar, Germany.Michael Pfreundschuh. MD, Med, Klinik I. Universitat des Saarlandes; Oscar-Orth-Str., 66421 Homburg/Saar. Germany. Tel.: 0049-6841-163002. Fax: 0049-6841-163101.Search for more papers by this author First published: June 1995 https://doi.org/10.1111/j.1600-065X.1995.tb00082.xCitations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References Allione, A. Consalvo, M., Nanni, P., Lollini, P. L., Cavallo, F. Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., Dellabona, P., Hock, H., Blankenstein, Th., Roscnthal, F. M., Gansbacher, B., Bosco, M, C, Musso. T., Gusella, L. & Forni, G. (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma ceils engineered with interleukin (IL)-2. IL-4. IL-6. IL-7, IL-10. tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferongene or admixed with conventional adjuvants. Cancer Res. 54, 6022– 6026. Anegon, I., Cuturi, M. C. Trinchieri, G. & Perussia, B. (1988) Interaction of Fc receptor (CDI6) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp. Med. 167, 452– 472. Ball, E. D., Guyre, P. M., Mills, L., Fisher, J., Dinces, N. B. & Fanger, M. W. (1992) Initial trial of bispecific antibody-mediated immunotherapy of CD 15 bearing tumors: cytotoxicity of human tumor ceils using a bispecific antibody comprised of anti-CD15 (MoAb PM8I) and anti-CD64/FcyRl (MoAb 32). J. Hemaloliwr 1, 85– 95. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J. & Glimcher, L. H. (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class 11 molecules. Proc. Nail. Acad Sci. USA 90, 5687– 5690. Beun, G. D. M., Gorter, A., Nooyen, Yv. De Velde, C. J. & Fleuren, G. J. (1993) T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model, II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T lymphocytes in vitro despite limited lysis in 51Cr release assays. J Immunol. 150, 2305– 2315. Beun, G. D. M.V., De Velde, J. H. & Fleuren, G. J. (1994) T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition Immunol. Today 15, 11– 14. Bjorndahl, J. M., Sung, S. S., Hansen, J. A. & Fu, S. M. (1989) Human T cell activation differential response to anti-CD38 as compared to anti-CD3 monoclonal antibodies. Eur. Immunol. 19, 881– 887. Bohlen, H., Hopff, T, Manzke, Q, Moldenhauer, G., Dörken, B., Von Fliedner, V, Diehl, V. & Tesch, H. (1994) Lysis of malignant B cells from patients with B–chronic lymphocytic leukemia by autologous T cells activated with CD3XCDI9 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82, 1803– 1812. Bolhuis, R. L. H., Lamers, C. H. J., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Di Re, E., Miotti, S., Raspagliesi, F. Rivoltini, L. & Colnaghi, M. I. (1992) Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: amulticenter study. Int. J. Cancer Suppl. 7, 78– 81. Bosma, G. C. Custer, R. P. & Bosma, M. J. (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301, 527– 531. Bosma, G. C., Fried, M., Custer, Ph., Carroll, A., Gibson, D. M. & Bosma, M. J. (1988) Evidence of functional lymphocytes in some (LEAKY) scid mice. J. Exp. Med. 167, 1016– 1033. van der Bruggen, P., Traversari, C Chomez, P., Lurqiun, C De Plaen, E. v. den Eynde, B., Knuth, A. & Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643– 1647. Bruynck, A., Seemann, G. & Bosslet, K. (1993) Characterisation of a humanised bispecific monoclonal antibody for cancer therapy. Br. J. Cancer 6, 436– 440. Chamow, S. M., Zhang, D. Z., Tan, X. Y., Mhatre, S. M., Marsters, S. A., Peers, D. H., Byrn, R. A., Ashkenazi, A. & Junghans, R. P (1994) A humanized bispecific immunoadhesion antibody that retargets CD3+ effeetors to kill HIV-1-infected cells. J. Immunol. 153, 4268– 4280. Chen, Q., Daniel, V. Maher D. W & Hersey, P (1994) Production of IL-IO by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56, 755– 760. Chen, L. Linstey, P. S. & Hellstrom, K. E. (1993) Costimulation of T cells for tumor immunity. Immunol. Today 14, 483– 486. Clark, M. R. & Waldmann, H. (1987) T-cell killing of target cells induced by hybrid antibodies: comparison of two monoclonal antibodies. J Natl. Cancer Inst. 79, 1393– 1401. Cole, D. J., Weil, D. P., Shamamian, P. RivoUini, L., Kawakami, Y., Topalian, S., Jennings, Ch. Eliyahu, S., Rosenberg, S. A. & Nishimura, M. I. (1994) Identification of MART-I specific T-cell receptors: T cell utilizing distinct T-cell receptor variable and joining region recognize the same tumor epitope. Cancer Res. 54 5265– 5268. Coulie, P. Q., Weynants, P., Lehmann, R Herman, J., Brichard, V, Wolfel, T.V. Pel, A. DePlaen, E. Brasseur, F. Boon, T. (1993) Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother 14 104– 109. Damle, N. K., Klussman, K., Linsley, P. S. & Aruffo, A. (1992) Differential costimulatory effects of adhesion molecules B7, ICAM-1. LFA-3 and VCAM-t in resting and antigen-primed CD4+ lymphocytes. J Immunol. 148, 1985– 1992. Demanet. C, Brissinck, J., Leo, O., Moser, M. & Thielemans, K. (1994) Role of T-cell subsets in the bispecific antibody (anti-idiotype X anti-CD3) treatment of the BCL1 lymphoma. Cancer Res. 54, 2973– 2978. DePalazzo. L. G., Gercel-Taylor, C. Kitson, J. & Weiner, L. M, (1990) Potentiation of tumorlysis by a bispecific antibody that binds to CA19–9 antigen and the FeyIII receptor expresssed by human large granular lymphocytes. Cancer Res. 50, 7123– 7128. DePalazzo, G. I., Holmes M., Gercel-Taylor, C. & Weiner, L. M. (1992) Antitumor effects of a bispecific antibody targeting CA19–9 antigen and CD16. Cancer Res. 52, 5713– 5719. Diehl, V, van Kalle, C., Fonatsch, C., Tesch, H., Juecker, M., & Schaadt, M. (1990) The cell of origin in Hodgkin's disease. Semin Oncol. 17, 660– 672. Dijk, J., Zegveld, S. T, Fleuren, G. J. & Warnaar, S. O. (1991) Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal–cell carcinoma xenografts: relative effects of size and affinity. Int. J. Cancer 48, 738– 743. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W. Groner, B., Jeschke, M., Lydon, N., McGlynn, F., Livingston, R. B., Moe, R. & Cheever, M. A. (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54, 16– 20. Doyle, A., Martin W. J., Funa, K., Gazdar, A., Carney, D. Martin, S. E., Linnoila, I., Cittita, E. Mulshine, J., Bunn, P & Minna, J. (1985) Markedly decreased expression of class I histocompatibility antigens, protein and MRNA in human small-cell lung cancer. J Exp. Med. 161 1135– 1151. Dürkop, H., Latza, U., Hummel, M., Eitelbach, F Seed, B., & Stein, H. (1992) Molecular cloning and expression of a new member of thenerve growth factor receptor family that is characteristic for Hodgkin's disease. Celt 68, 421– 427. Elliot. B-E., Carlow, D. A., Rodricks, A. & Wade, A, (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53, 181– 245. Engert, A., Martin, G., Pfreundschuh, M., Amlot, P., Hsu, S. M., Diehl, V. & Thorpe. P (1990) Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 53, 2929– 2935. Eshhar, Z., Waks, T. Gross, G. & Schindler D. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T–cell receptors. Proc. Natl. Acad Sci. USA 85, 5879– 5883. Fanger, M. W. Morganelli. P M. & Guyre. P. M. (1992) Bispecific antibodies. Crit. Rev. Immunol. 12, 101– 124. Fanger, M. W. Shen, L., Graziano, R. F & Guyre. P. M. (1989) Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today 10, 92– 97, Eerrini, S., Cambiaggi, A., Cantoni, C, Canevari, S., Mezzanzanica, D., Colnaghi, M. I. & Moretta, L. (1992) Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: Role of different triggering molecules. Int. J. Cancer Suppl, 7, 15– 18. Ferrini, S., Miescher, S., Zocchi, M. R., v Fliedner, V. & Moretta, A. (1987) Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels. J Immunol. 138, 1297– 1302. Ferrini, S., Sforzini, S., Camniaggi, A., Poggi, A., Meazza, R., Canevari, S., Colnaghi, M. I. & Moretta, L. (1994) The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int. J. Cancer 56, 846– 852. Flamand, Y., Biernaux, C. V. Mechelen, M., Sornasse, T, Urbain, J., Leo, O. & Moser, M. (1990) Immune surveillance: both CD3+ CD4+ and CD3+ CD8+ T cells control in vivo growth of P815 masctocytoma. Int. J. Cancer 45, 757– 762. Flens, M. J., Mulder, W M. C. Bril, H. von Blombeg van de Flier, M. B., Scheper, R. J. V. & Her, R. A. (1993) Efficient expansion of tumor-infiltrating lymphocytes from solid tumorsby stimulation with combined CD3 and CD28 monoclonal antibodies. Cancer Immunol. Immunother. 37, 323– 328. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J.J., Kudoh, S., Klein, E., Bukowski, R. M. & Ochoa, A. C (1993) Loss of T-cell receptor chain and p56lck in T-cells infiltrating human renal cell carcinoma. Canter Res. 53, 5613– 5616. Fraser, J. D. & Weiss, A. (1992) Regulation of T–cell lymphokine gene transcription by the accessory molecule CD28. Mot. Ce1l. Biol. 12, 4357– 4363. Freedman, A. S., Freeman, G. J., Rhynhart, K. & Nadler, L. M. (1991) Selective induction of B7/BB1 on interferon––stimulated monocytes: a potential mechanism for amplification of T cell activation through CD28 pathway Ceil. Imtnunot. 137, 429– 437. Freeman, G. J., Borriello, F. Hodes, R. J., Reiser, H., Hathcovk, K. S., Laszlo, G., McKnight, A. J., Kim, J., Du, L., Lombard, D. B., Gray, G. S., Nadler, L. M. & Sharpe, A. H. (1993) Uncovering of functional alternative CTLA44–4 counter–receptor in B7–deficientmice. Science 262, 907– 909. Freeman, G. J. Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F & Nadler, L. M. (1989) B7, a new member of the Ig superfamily unique expression on activated and neoplastic B cells. J. Immunol 143, 2714– 2722. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Sugita, K., Freedman, A. S., Morimoto, C. & Nadler, L. M. (1991) Human T–cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 88, 6586– 6590. Greenberg, P. D. (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv: Immunol. 49, 281– 355. Haagen, I. A., Geerars, A. J., De Lau, W. B., Clark, M. R. V., De Griend, R. J., Bast, B. J. & De Gast, B. C. (1994) Killing of autologous B-lineage malignancy using CD3 X CD19 bispecific antibody in end stage leukemia and lymphoma. Blood 84, 556– 563. Hahn, W. C., Burakoff, S. J. & Biere, B. E. (1993) Signal transduction pathways involved in T cell receptor–induced regulation of CD2 avidity for CD58. J Immunol. 150, 2607– 2619. Hara. T, Fu, S. M. & Hansen, J. A. (1985) Human T cell activation II. A new activation pathway used by a major T cell population via a disutfide-bonded dimer of a 44 kilodalton polypeptide (9. 3) antigen. J Exp. Med. 161, 1513– 1524. Harding, F. A., McArthur, J. G., Gross, H. A., Raulet. D. H. & Allison, J. P (1992) CD28 mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607– 609. Harlan, D. M., Hengartner, H., Huang, M. L., Kang, Y.-H., Abe, R., Moreadith, R. W. Pircher, H., Gray, G. S., Ohashi. P. S., Freeman, G. J., Nadler, L. M., June, C. H. & Aichele P (1994) Mice expressing both B7-i and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a break–down of lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA 91, 3137– 3141. Harris, D. T. Friedmann, L. J. & Fvans, D. L, (1994) Target-cell sensitivity to natural killer-cell lysis is determined by the expression of a novel antigen in conjunction with a major histocompatibility complex class-I molecule. Scand. J. Immunol. 39, 73– 78. Hellslröm, K. E. & Hellström, I. (1993) Tumor immunology: an overview. Ann. N. Y. Acad. Sci. 690, 24– 33. Herberman, R. B. & Gaylord, C. E. (1973) Conference and workshop on cellular immune reactions to human tumor-associated antigens. Natl. Cancer Inst. Monogr. 37, 1– 15. Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamantstcin, T. & Blankenstein, Th. (1993) Mechanism of rejection induced by tumor cell-targeted gene transfer of interleu-kin-2, interleukin-4.interleukin-7, tumor necrosis factor, or interferon. Proc. Natl. Acad Sci. USA 90, 2774– 2778. Holliger, P, Prospero, T. & Winter, G. (1993) Diabodies: Small bivalent and bispecific antibodyfragments. Proc. Nail Acad Sci. USA 90, 6444– 6448. Hombach, A., Jung, W., Pohl, C Renner, C., Sahin, U., Schmits, R., Wolf, J., Kapp, U Diehl, V. & Pfreundschuh, M. (1993) A CD16/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated Natural Killer cells in vitro and in vivo. Int. J Cancer. 55, 830– 837. Hoon, D. S. B., Hayashi, Y., Morisaki, T. Foshag, L. J. & Morton, D. L. (1993) Interleukin-4 plus tumor necrosis factor α augments the antigenicity of melanoma cells. Cancer Immunol. Immunother. 37, 378– 384. Howell, A. L., Guyre. P. M., You, K.-S. & Fanger, M. W (1994) Targeting HIV–I to FcγR on human phagocytes via bispecific antibodies reduces infectivity of HIV-l to T cells. J Leucoc. Biol. 55, 385– 391. Hudig, D Allison, N. J. Pickett, T. M., Winkler, U. Kam, C. & Powers, J. C. (1991) The function of lymphocyte proteases: Inhibition and restoration of granule-mediated lysis with isocumarin serine protease inhibitors. J. Immunol. 147, 1360– 1368. Huizinga, T. W. v. der Schoot, C. E., Jost, C, Klaassen, R., Kleijer, M.V., dem Borne, A. E., Roos, D. & Tetteroo, P. A. (1988) The Pl-linked receptor FcRIII is released on stimulation of neutrophils. Nature 333, 667– 669. Hwu. P & Rosenberg, S. A. (1994) The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detec. Prev. 18, 43– 50. Hwu, P. Shafer, G. F., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A. & Eshhar, Z. (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor y chain. J Exp. Med. 178, 361– 366. June, C. H., Bluestone, J. A., Nadler, L. M, & Thompson, C. B. (1994) The B7 and CD28 receptor families. Immunol. Today 15, 321– 331. June, C. H., Ledbetter, J. A., Linsley, P. S. & Thompson, C. B. (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11, 211– 216. Jung, G., Ledbetter, J. A. & Muller-Eberhard, H. J. (1987) Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Nail Acad. Sci. USA 84, 4611– 4615. Kägi, D. Ledermann, B., Bürki, K., Seiler, P. Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M. & Hengartner. H, (1994) Cytotoxicity mediated by T cells and natural killer ceils is greatly impaired in perform-deficient mice. Nature 369, 31– 37. Kang, S.-M., Beverly, B., Tran, A.-C. Brorson, K., Schartz, R. H. & Lcnardo, M. J. (1992) Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 251, 1134– 1138. Kapp, U., Wolf, J., V, Kalle. C., Stein, H., Fonatsch, C., Schell-Frederick, E. & Diehl, V. (1992) Recentefforts lo establish an in-vivo model as a new experimental tool in the study of Hodgkin's disease. Em: J. Cancer 28A, 1408– 1411. Karpovsky, B., Titus, J. A., Stephany, D. A. & Segal, D. M. (1981) Production of target specific cells using hetero-cross-linked aggregates containing anti-target cells and anti-Fey receptor antibodies, J. exp. Med. 160, 1686– 1701. Kawakami, Y., Haas, G. P & Lotze, M. T. (1993) Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J Immunother. 14, 336– 347. Kostelny, S. A., Cole, M. S. & Tso, J. Y. (1992) Formation of a bispecific antibody by the use of leucine zippers. J Immunol 148, 1547– 1553. Krahenbuhl, O. & Tschopp, J. (1991) Perforin-Induced pore formation. Immunol. Today 12, 399– 402. Kroesen, B.J., Ter Haar, A., Spakman, H., Willemse, P., Sleijfer, D. Th., De Vreis, E. G. E., Mulder, N. M., Berendsen, H. H., Limburg, P C, The, T. H. & de Leij, L. (1993) Local antitumor treatment in carcinoma patients with bispecific–monoclonal-antibody redirected T cells. Cancer Immunol. Immunother, 37, 400– 407. Lafreniere, R. & Rosenberg, S. A. (1985) Successful immunotherapy of murine experimental hepatic metastases with Iymphokine-activated killer cells and recombinant interleukin-2. Cancer Res. 45, 3735– 3741. Lanier, L. L., Phillips, J. H., Hackett Jr, J., Tutt, M. & Kumar, V. (1986) Natural killer cells: definition of a cell type rather than a function. J. Immunol. 137, 2735– 2739. Lanier, L. L. & Phillips, J. H. (1988) Effectors, rep ertoire and receptors involved in lymphocyte–mediated MHC–unrestricted cytotoxicity. Ann. Inst. Pasteur. Immunol. 139, 450– 456. Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W. Gibson, M. G., Linsley, P. S. & Bluestone, J. A. (1992) Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 251, 789– 792. Liao, F., Shin, H. S. & Rhee, S. G. (1993) Cross-linking of Fc gamma RIIIA on natural killer cells results in tyrosine phosphorylation of PLC-gamma 1 and PLC-gamma 2. J. Immunol. 150, 2668– 2674. Lichtenheld Olsen, K. J., Lu, P. Lowrey, D. M., Hameed, A., Hengartner, H. & Podack, E. R. (1988) Structure and function of human perforin. Nature 335, 448– 451. Lindsten. T, June, C. H., Ledbetter, J. A., Stella, G. & Thompson, C. B. (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244, 339– 343. Linsley. P. S., Brady, W. Grosmair, L., Aruffo, A., Damle, N. K. & Ledbetter, J. A. (1991) Binding of the B activation antigen B7 to CD28 costimulated T-cell proliferation and IL–2 MRNA accumulation. J. Exp. Med. 173, 721– 730. Linsley, P. S. & Ledbetter, J. A. (1993) The role of the CD28 receptor during T cell responses lo antigen. Annu. Rev. Immunol. 11, 191– 212. Lippman, M. E. (1993) The development of biological therapies for breast cancer. Science 259, 631– 632. Liu, Y. & Linsley, P. S. (1992) Costimulation of T-cell growth. Curr. Opin. Immunol. 4, 265– 270. Maas, R. A., Dullens, H. F J. & Otter, W. D. (1993) Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141– 148. Mantovani, A., Botazzi, B., Colotta, F. Sozzani, S. & Ruco, L. (1992) The origin and function of tumor-associated macrophages. Immunol. Today 13, 265– 270. Martin, D. E., Zalman, L. S., Jung, G. & Müller-Eberhard, H. J. (1987) Induction of synthesis of the cytolytic C9 (ninth component of complement)-related protein in human peripheral mononuelear cells by monoclonal antibody OKT3 or inlerleukin 2: correlation with cytotoxicity and lymphocyte phenotype. Proc: Natl. Acad. Sci. USA 84, 2946– 2950. Mazumder, A. & Rosenberg, A. S. (1984) Successful immunotherapy of NK-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. Science 255, 1487– 1489. Melief, C. J. (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143– 175. Mendelsohn, J. (1990) The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin. Cancer Biol. 1, 339– 344. Meuer, S. C, Hussey. R. E., Fabbi, M., Fox, D., Acuto, O., Fitzgerald, K. A., Hodgdon, J. C. Protentis, J. P. Schlossman, S. F. & Reinherz, E. L. (1984) An alternative pathway of T-cell activation: a functional role for the 50KD T 11 sheep erythrocyte receptor Cell 36, 397– 400. Mezzanzanica, D., Garrido, M. A., Neblock, D. S., Daddona. P. E., Andrew, S. M., Zurawski, V. R., Segal, D. M. & Wunderlich, J. R. (1991) Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51, 5716– 5721. Miller, R. A., Oserdoff, A. R., Stratte, P.T & Levy, R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988– 995. Milstein, C. & Cuello, A. C. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305, 537– 540. Moller, S. A. & Reisfeld, R. A. (1991) Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes. Cancer Immunol. Immunother. 33 210– 216. Monaco, J. J., Cho, S. & Attaya, M. (1990) Transport protein genes in the murine MHC: possible implication for antigen processing. Science 250, 1725– 1726. Moretta, A. Vitale, M., Sivori, S., Bottino, C Morelli, L., Augugliaro, R., Barbaresi, M., Pende, D., Ciccone, E., Lopez-Botet, M. & Moretta. L (1994). Human natural killer cell receptors for HLA–class I molecules. Evidence that the Kp43 (CD94) molecule functions as recptor for FMA-B alleles. J Exp. Med. 180, 545– 555. Moretta, A., Ciccone, E., Pantaleo, G., Tambussi, G., Bottino, C, Melioli, G., Mingari, M. C. & Moretta, L. (1989) Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans. Immunol. Rev, 111, 145– 175. Morgan, D. A., Ruscetti. F. W. & Gallo, R. G. (1976) Selective in vitro growth of T-lymphocytes from normal bone marrow. Science 193, 1007– 1008. Morganelli. P. M., Kitzmiller, T. J., Hemmer, R. & Fanger, M. W. (1992) Redirected targeting of LDL to human monocyte Fey receptors with bispecific antibodies. Arterio. scler Thromb. 12, 1131– 1137. Mulé, J. J., McIntosh, J. K., Jablons, D. M. (1990) Antitumor activity of recombinant interleukin–6 in mice. J. Exp. Med. 171, 629– 639. Nakagomi, H. Petersson, M., Magnusson, I., Juhlin, C. Matsuda, M., Mellstedt, H., Taupin, J.-L., Vivier, E., Anderson, P. & Kiesling, R. (1993) Decreased expression of the signal-transducing z chain in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Re. 53 5610– 5612. Nakajima, H. & Henkart, P. A. (1994) Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown. J. Immunol. 152, 1057– 1063. Nakamura, Y. Wakimoto, H., Abe, J., Kanegae, Y. Saito. Lni Aoyagi, M., Kikiyoshi, H. & Haniada, H. (1994) Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 54, 5757– 5760. Nijhuis, E. W. P. Wiel van Kemenade, E., Figdor, C. G. V. & Lier, R. A. W. (1990) Activation and expansion of tumour-infitirating lymphocytes by anti–CD3 and anti–CD28 monoclonal antibodies. Cancer Immunol. Immunother. 32, 245– 250. Nishioka, W. K. & Welsh, R. M. (1994) Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target. J Exp. Med. 179, 769– 774. Nitta, T. Sato, K., Yagita, H., Okumura, K. & Ishii, S. (1990) Preliminary trial targeting therapyagainst malignant glioma. Lancet 335, 368– 371. Paik, S., Burkhard, E. & Lippman, M. E. (1992) Clinical significance of erh-B2 protein overexpression. Cancer Treat. Res. 61, 181– 191. Pardoll, D. M. (1993) Cancer vaccines. Immunol. Today 14, 310– 316. PEREZ, P. Hoffman, R. W., Shae, S., Bluestone, J. A. & Segal, D. M. (1985) Specific targeting of cytotoxic T cells by anti-Te conjugates. Nature 316, 354– 356. Perussia, B., Dayton, E. T. Lazarus, R., Fanning, V. & Trinchieri, G. (1983) Immune interferon induces the receptor for monomeric IgGI on human monocytic and myeloid cells. J. Exp. Metl. 158, 1092– 1113. Petroni, K. C. Shen, L. & Guyre, P. M. (1988) Modulation of human polymorphonuclear leucocyte IgG Fc receptors and Fc receptor–mediated functions by IFN–gamma and glucocorticoids. J Immunol. 140, 3467– 3472. Phillips, J. H., Takeshita, T, Sugamura, K. & Lanier, L. L. (1989) Activation of natural killer cells via the p75 interleukin 2 receptor. J. Exp. Med. 170, 291– 296. Pohl, C., Denfeld, R., Renner, C. Jung, W. Bohlen, H., Sahlin, U., Hombach, A., van Lier, R., Schwonzen, M., Diehl, V & Pfreundschuh, M. (1993) CD30 antigen specific targeting and activation of T cells via murine bispecific monoelonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer 54, 820– 827. Powis, S. J., Deverson, E. V. Coadwell, W. J., Ciruela, A., Huskisson, N. S., Smith, H., Butcher, G.W. & Howard, J. C. (1992) Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 357, 211– 215. Pupa, S., Canevari, S., F'ontanelli, R., Menard, S., Mezzanzanica, D. Lanzavecchia, A. & Colnaghi, M. I. (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody induced lysis of human carcinoma ceils. Int. J. Cancer 42, 455– 459. Qian, J.-H., Ttius, J. A., Andew, S. M., Mezzanzanica, D. Garrido, M. A., Wunderlich, J. R. & Segal, D. M, (1991) Human peripheral blood lymphocytes targeted with bispecific antibodies release cylokine